Precision Biosciences: A Critical 2026 for Key Clinical Programs

Precision Biosciences US74019P2074

The year 2026 is shaping up to be a pivotal period for Precision Biosciences, with the biotech firm prioritizing the advancement of its two flagship ARCUS-based in vivo gene editing therapies. The company’s financial runway and clinical execution will be under scrutiny as it works toward significant milestones for its hepatitis B and Duchenne muscular dystrophy candidates.

As of December 31, 2025, Precision Biosciences reported holding approximately $137 million in liquid assets, comprising cash, cash equivalents, and restricted cash. Management projects this capital is sufficient to fund operations through several key data readouts extending into 2028. The financial position was bolstered in late 2025 by an $8 million one-time payment linked to progress in partner programs, including ECUR-506 and azer-cel.

The company’s stock recently traded at €3.44, hovering roughly 10% below its 52-week high. Elevated share price volatility is common for biotechnology firms approaching major clinical data disclosures.

PBGENE-HBV: Seeking a Functional Cure

For its PBGENE-HBV program targeting chronic hepatitis B, the focus remains on the ongoing Phase 1/2a ELIMINATE-B trial. Early data from multiple dose cohorts have shown encouraging safety and antiviral signals. The immediate objective is to complete dosing in cohorts 3, 4, and 5 to identify a regimen that could potentially allow patients to discontinue nucleos(t)ide analogue therapy—a prerequisite for expanding the clinical study.

Additional liver biopsy data are scheduled for release in the first half of 2026, with further updates expected at medical conferences later in the year. Clear evidence of antiviral effects with an acceptable safety profile from these biopsies could pave the way for a broader trial.

PBGENE-DMD: Anticipating Clinical Initiation

The timeline for PBGENE-DMD, aimed at treating Duchenne muscular dystrophy (DMD), is also advancing. Precision Biosciences anticipates receiving Investigational New Drug (IND) clearance from regulators in the first quarter of 2026. Subject to that approval, patient dosing in the Phase 1/2 FUNCTION-DMD study is planned to commence shortly thereafter, in early 2026.

Initial clinical data from multiple patients enrolled in this trial are projected by the end of 2026. Any delays in the IND process or clinical start would consequently push back this data timeline and increase pressure on the company’s financial resources.

Key 2026 Milestones at a Glance

• Q1 2026: Expected IND clearance for PBGENE-DMD.
• Early 2026: Planned initiation of patient treatment in the FUNCTION-DMD study.
• First Half 2026: Additional PBGENE-HBV biopsy data.
• Late 2026: Initial multi-patient data readout for PBGENE-DMD.

The coming year will be decisive for Precision Biosciences. Successful execution on these clinical fronts could generate significant value, while any setbacks would extend development timelines and test the resilience of its current cash reserves.